Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 28 Jan 2021
Prescription drug rices in the U.S. are 2.56 times higher than other nations – brand-named drugs 3.44 times higher
27 January 2021 - Prescription drug prices in the United States are significantly higher than in other nations, with prices ...
Posted by Michael Wonder on 28 Jan 2021
M6P Therapeutics receives six rare paediatric disease designations from the U.S. FDA for company’s deep pipeline of programs for lysosomal storage disorders
28 January 2021 - U.S. FDA also grants two orphan drug designations for the company’s gene therapy programs for Gaucher disease ...
Posted by Michael Wonder on 28 Jan 2021
Bio-Thera Solutions announces FDA accepts biologics license application for BAT1706, a proposed biosimilar to Avastin
28 January 2021 - Bio-Thera Solutions today announced that the U.S. FDA has accepted its biologics license application for BAT1706, a ...
Posted by Michael Wonder on 28 Jan 2021
Advocacy groups urge Biden administration not to tap Woodcock as FDA commissioner
27 January 2021 - As the Biden White House attempts to fashion its health policies, a coalition of consumer and ...
Posted by Michael Wonder on 28 Jan 2021
Clarification of Comirnaty dosage interval
28 January 2021 - EMA’s human medicines committee (CHMP) has updated the product information for the COVID-19 vaccine Comirnaty to ...
Posted by Michael Wonder on 28 Jan 2021
TGA to rule on psychedelic drug access for mental health problems
28 January 2021 - A group of prominent Australians is continuing to push for greater access to psychedelic drugs to ...
Posted by Michael Wonder on 28 Jan 2021
Alberta announces funding for pricey gene therapy drug Zolgensma
Alberta Health Minister Tyler Shandro announced funding Wednesday for the gene therapy Zolgensma, which is used to treat toddlers with ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 27 Jan 2021
E.U. and U.K. fighting over scarce vaccines
27 January 2021 - As vaccine production falls behind schedule, and the European Union lags in inoculating people, Brussels and London ...
Posted by Michael Wonder on 27 Jan 2021
NICE publishes final guidance on new use for Lonsurf
27 January 2021 - NICE has completed its review of trifluridine with tipiracil hydrochloride for the treatment of patients with ...
Posted by Michael Wonder on 27 Jan 2021
EU demands UK made AstraZeneca vaccine doses
27 January 2021 - The EU has urged pharmaceutical firm AstraZeneca to supply it with more doses of its COVID-19 ...
Posted by Michael Wonder on 27 Jan 2021
European Medicines Agency accepts GBT’s marketing authorisation application for Oxbryta (voxelotor) for the treatment of haemolytic anemia in sickle cell disease
27 January 2021 - Global Blood Therapeutics today announced that the EMA has completed the validation of GBT’s marketing authorisation application ...
Posted by Michael Wonder on 27 Jan 2021
Coronavirus: EU threat to Australia’s vaccine program
27 January 2021 - A European move to shore up supplies of both the Pfizer/BioNTech and Oxford/AstraZeneca vaccines looks to ...
Posted by Michael Wonder on 27 Jan 2021
Australia’s COVID-19 vaccine information campaign begins
27 January 2021 - The Australian Government’s $23.9 million public information campaign to encourage Australians to get a COVID-19 vaccine begins ...
Posted by Michael Wonder on 27 Jan 2021
Government rejects claim overseas production issues threaten access to vaccines
27 January 2021 - The entire population could be vaccinated against COVID-19 in as little as 6½ months, meaning it's ...